Document:

EX-10.1

   

  EXHIBIT 10.1

   

  FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT

   

  This FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT  (this

  “Fifth Amendment”) is made and entered into as of August 31, 2021 (the “Fifth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”

   

  WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020, October 28, 2020, February 4, 2021, and June 23, 2021 (the “Original Agreement”); and WHEREAS, the Parties desire to make certain further amendments to the Original Agreement;

   

  NOW, THEREFORE, in consideration of the promises and covenants contained in this Amendment, and intending to be legally bound, the Parties hereby agree as follows:

   

  1.Interpretation. Capitalized terms not defined in this Fifth Amendment have the meanings given such terms in the Original Agreement. References to Sections and Schedules herein will be to Sections and Schedules of the Original Agreement, except as otherwise noted.

   

  2.Amendments.

   

  a.Section 8.6.1 shall be deleted and replaced by the following:

   

  Development Supply Agreement.  Unless otherwise agreed by the Parties, no later  than

  (a)November 30, 2021, with regards to the Lead Product, and (b) no later than nine months following the effective date of exercise of the Option with regards to every other Licensed Product to which this Article 8 (Manufacturing and Supply) applies in accordance with Section 8.1, (or such other time as agreed by each Party), the Parties will negotiate in good faith and enter into a supply agreement on reasonable and customary terms for the supply of such Licensed Product by Sarepta to Roche in the Roche Territory at the Supply Price (the “Development Supply Agreement”), and a related quality agreement, which agreements will govern the terms and conditions of the Manufacturing of such Licensed Product for Development purposes. The Parties may choose to combine into a single agreement the Development Supply Agreement and the Commercial Supply Agreement for a Licensed Product.

   

  b.Section 8.6.2 shall be deleted and replaced by the following:

   

  Commercial Supply Agreement.  Unless otherwise agreed by the Parties, no later   than

  (a)November 30, 2021, with regards to the Lead Product, and (b) no later than twelve (12) months following the effective date of the Option Exercise with regards to every other Licensed Product to which this Article 8 (Manufacturing and Supply) applies in accordance with Section 8.1, (or such other time as agreed by each Party), the Parties will negotiate in good faith and enter into a commercial supply agreement on reasonable and customary terms for the commercial-grade supply of such Licensed Product by Sarepta to Roche in 

   

  1

  

   

  the Roche Territory at the Supply Price (the “Commercial Supply Agreement” 

  and together with the Development Supply Agreement, the “Supply Agreements”), and a related quality agreement, which agreements will govern the terms and conditions of the Manufacturing and supply of such Licensed Product for Commercialization purposes. As noted above, the Parties may choose to combine into a single agreement the Development Supply Agreement and the Commercial Supply Agreement for a Licensed Product,

  3.Effect on Original Agreement. Except as specifically amended by this Fifth Amendment, the Original Agreement will remain in full force and effect and is hereby ratified and confirmed. Each future reference to the Original Agreement will refer to the Original Agreement as amended by this Fifth Amendment. To the extent a conflict arises between the terms of the Original Agreement and this Fifth Amendment, the terms of this Fifth Amendment shall prevail but only to the extent necessary to accomplish their intended purpose.

   

  4.Incorporation. Article 17 of the Original Agreement is hereby incorporated mutatis mutandis into this Amendment.

   

  5.Binding Effect. This Fifth Amendment will be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns.

   

  6.Authority. As of the Fifth Amendment Effective Date, each Party hereby represents and warrants that

  (a) it has the power and authority to execute and deliver this Fifth Amendment, (b) the execution, delivery, and performance of this Fifth Amendment by it has been duly authorized by all requisite corporate action, and (c) this Fifth Amendment has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms.

   

  7.Governing Law. This Fifth Amendment and all amendments, modifications, alterations, or supplements hereto, and the rights of the Parties, will be construed under and governed by the laws of the State of New York, United States, exclusive of its conflicts of laws principles.

   

  8.Amendments. This Fifth Amendment may not be modified or amended, except by another agreement in writing executed by duly authorized signatories of each Party.

   

  9.Counterparts. This Fifth Amendment may be executed in two or more counterparts, all of which taken together will be regarded as one and the same instrument. Each Party may execute this Fifth Amendment in AdobeTM Portable Document Format (PDF) sent by electronic mail. PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Fifth Amendment.

   

  [Signatures Follow]

   

   

  2

  

   

  IN WITNESS WHEREOF, the Parties have executed this Fifth Amendment to License, Collaboration, and Option Agreement through their duly authorized representatives.

   

  Sarepta Therapeutics Three, LLC

   

  By: /s/ Adam Hopkin

  Name: Adam Hopkin

  Title: Manager

   

   

   

  F. Hoffmann-La Roche Ltd

   

  By: /s/ Claire Steers		
Name: Claire Steers
Title: Global Alliance Director

   

  By: /s/ Barbara Schroeder de Castro Lopes
Name: Barbara Schroeder de Castro Lopes
Title: Authorized Signatory

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

  [Signature Page To Fifth Amendment To License, Collaboration, and Option Agreement]

   

  3Document

AMENDMENT NO. 6 TO AFFILIATION AGREEMENT

This AMENDMENT NO. 6 (this “Amendment”) to the Affiliation Agreement, dated as of August 28, 2011 (as amended from time to time, the “Affiliation Agreement”), by and among TotalEnergies Solar INTL SAS, formerly known as Total Gas & Power USA, SAS, a société par actions simplifiée organized under the laws of the Republic of France, TotalEnergies Gaz Electricité Holdings SAS, formerly known as Total Gaz Electricité Holdings France SAS, a société par actions simplifiée organized under the laws of the Republic of France (together, “Parent”) and SunPower Corporation, a Delaware corporation (the “Company”), is made and entered into as of October 29, 2021 by and between the Parent and the Company. Capitalized terms used in this Amendment and not otherwise defined shall have the meaning given to them in the Affiliation Agreement.

WITNESSETH:

WHEREAS, Parent and the Company desire to amend the Affiliation Agreement to reflect certain changes to the composition of the Company’s Board of Directors, as set forth below.

NOW, THEREFORE, in consideration of the foregoing premises and the matters set forth herein, as well as other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged and accepted, and intending to be legally bound, Parent and the Company hereby agree as follows:

1. Amendment.

a. Section 3.2(l) of the Affiliation Agreement shall be amended in its entirety to read as follows:

(l) Temporary Changes to Board Composition. Notwithstanding anything in Section 3.2(a) or 
Section 3.2(d) to the contrary:

(i)    On or prior to April 19, 2021, the Company Board shall take all action necessary to increase the size of the Company Board to eleven (11) directors.

(ii)    From April 19, 2021 until November 1, 2021 (or such earlier date as may be designated by the Company Board) (such date, the “Reversion Date”), the Company Board shall consist of (i) the Chief Executive Officer of the Company, (ii) the immediate past Chief Executive Officer of the Company, who shall serve as Chairman of the Company Board (the “Transitional Chairman”), (iii) three (3) Disinterested Directors, (iv) subject to Section 3.2(d), six (6) Terra Directors, and (v) such number of Disinterested Directors as to fill any vacancies on the Company Board resulting from a reduction in the number of Terra Directors pursuant to Section 3.2(d), in each case taking into account the provisions of Section 3.1(f).

(iii)    Upon the Reversion Date, the Transitional Chairman shall resign from his position on the Company Board, and the resulting vacancy shall be filled with one (1) additional Disinterested Director elected by the Company Board.

b. A new subsection shall be added to Section 3.2 of the Affiliation Agreement, to read as follows:

(m) Additional Temporary Changes to Board Composition. Notwithstanding anything in 
Section 3.2(a) or Section 3.2(d) to the contrary:

(i)    On or prior to the Reversion Date, the Company Board shall take all action necessary to retain the size of the Company Board at eleven (11) directors.

(ii)    From the Reversion Date until March 31, 2022 (or such earlier date as may be designated by the Company Board) (such date, the “Second Reversion Date”), the Company Board shall consist of (i) the Chief Executive Officer of the Company, who shall serve as Chairman of the Company Board, (ii) four (4) Disinterested Directors, (iii) subject to Section 3.2(d), six (6) Terra Directors, and (iv) such number of Disinterested Directors as to fill any vacancies on the Company Board resulting from a reduction in the number of Terra Directors pursuant to Section 3.2(d), in each case taking into account the provisions of Section 3.1(f).

(iii)    Upon the Second Reversion Date, (A) one of the Disinterested Directors, in consultation with the Nominating and Corporate Governance Committee, shall resign from his or her position on the 

Company Board, (B) Terra shall as promptly as practicable cause one (1) Terra Director to resign from the Company Board, and (C) the Company Board shall take all action necessary to reduce the size of the Company Board to nine (9) directors, such that the Company Board shall consist of (i) the Chief Executive Officer of the Company, who shall serve as Chairman of the Company Board, (ii) three (3) Disinterested Directors, (iii) subject to Section 3.2(d), five (5) Terra Directors, and (iv) such number of Disinterested Directors as to fill any vacancies on the Company Board resulting from a reduction in the number of Terra Directors pursuant to Section 3.2(d), in each case taking into account the provisions of Section 3.1(f).

2. Agreement. All references to the “Agreement” set forth in the Affiliation Agreement shall be deemed to 
be references to the Affiliation Agreement as amended pursuant to this Amendment.

3. Headings. The headings set forth in this Amendment are for convenience of reference purposes only and 
shall not affect or be deemed to affect in any way the meaning or interpretation of this Amendment or any 
term or provision hereof.

4. Ratification. Article I shall be deemed modified as of the date of this Amendment. Other than as 
expressly modified pursuant to this Amendment, all provisions of the Affiliation Agreement, as amended 
prior to the date of this Amendment are hereby ratified and remain unmodified, and in full force and effect.

(Remainder of Page Left Intentionally Blank)

IN WITNESS WHEREOF, the undersigned have caused this Amendment No. 6 to be executed by their respective duly authorized officer to be effective as of the date set forth above.

									
		TOTALENERGIES SOLAR INTL SAS
			
			
		By:	/S/ Bruno Leconte
		Name:	Bruno Leconte
		Title:	Director General

			
			
		TOTALENERGIES GAZ ELECTRICITÉ HOLDINGS SAS
			
			
		By:	 /S/ Laurent Wolffsheim

		Name:	Laurent Wolffsheim
		Title:	Authorized Signatory

			
			
		SUNPOWER CORPORATION
			
			
		By:	 /S/ Peter Faricy

		Name:	Peter Faricy
		Title:	President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]